Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orthobiological Therapies in Musculoskeletal Conditions
NCT07434115Phase 1Recruiting
- Sponsor
- ProRegen
- Start
- Sep 2026
- Primary completion
- Jan 2029
- Modality
- Polymer-based Nanoparticles, Adipose-derived MSCs, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of platelet-rich plasma, autologous bone marrow cell concentrate, hyaluronic acid and microfragmented adipose tissue in Musculoskeletal diseases, sponsored by ProRegen. Primary endpoints: Pain scale at 2 years and Joint function at 2 years. Started Sep 2026; status: recruiting.
02
Drugs
platelet-rich plasmaautologous bone marrow cell concentratehyaluronic acidmicrofragmented adipose tissue
03
Conditions
Musculoskeletal diseases
Beyond the preview
Go deeper on NCT07434115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07434115.